Nan Fung Group Holdings Ltd
KAI TAK, K3 · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$149.7M2026 Q3
Positions29
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.75.7%
What Changed This Quarter?
Top Holdings
LBRX
LB Pharmaceuticals
16.2%
MPLT
MapLight Therapeutics
15.7%
OBX
Obsidian Therapeutics
8.4%
HELP
Helus Pharma
8.1%
EVMN
Evommune
8.0%
NUVB
Nuvation Bio
5.0%
INCY
Incyte
4.4%
ONC
BeOne Medicines
3.8%
New / Increased
5 new · 2 increased
OBXNEW
Obsidian Therapeutics
8.4%
NUVBNEW
Nuvation Bio
5.0%
NAMSNEW
Newamsterdam Pharma
2.7%
Tcgx Acquisit…NEW
TCGX Acquisition
1.7%
BRVENEW
Braveheart Bio
1.1%
MPLT
Maplight Therapeutics
15.7%
+136.8%
PCOR
Procore Technologies
3.1%
+66.7%
Reduced / Exited
1 reduced · 1 sold out
RXRX
Recursion Pharmaceuticals In
0.5%
-69.5%
CHYMEXIT
Chime Financial
0.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.